This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA)

Tipranks - Tipranks - Wed Jun 17, 4:45AM CDT

Analysts fell to the sidelines weighing in on enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Claim 55% Off TipRanks

enGene Holdings (ENGN)

Wells Fargo analyst Yanan Zhu assigned a Hold rating to enGene Holdings yesterday and set a price target of $2.00. The company’s shares closed last Monday at $1.77.

According to TipRanks.com, Zhu is a 5-star analyst with an average return of 15.4% and a 37.2% success rate. Zhu covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Crispr Therapeutics AG, and Taysha Gene Therapies. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for enGene Holdings with a $5.93 average price target, which is a 238.9% upside from current levels. In a report issued on June 11, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $1.50 price target.

See today’s best-performing stocks on TipRanks >>

Intellia Therapeutics (NTLA)

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Intellia Therapeutics yesterday and set a price target of $19.00. The company’s shares closed last Monday at $14.92.

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 5.0% and a 47.3% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Perspective Therapeutics, and Crispr Therapeutics AG. ;'>

Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.06, which is a 64.8% upside from current levels. In a report issued on June 10, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $13.00 price target.

Read More on ENGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).